Robert E. DAVIS;Carl-Magnus A. ANDERSSON;Mark R. BRANN;Allan K. ULDAN;David M. WEINER
发明人:
David M. WEINER,Robert E. DAVIS,Mark R. BRANN,Carl-Magnus A. ANDERSSON,Allan K. ULDAN
申请号:
US13750778
公开号:
US20130137727A1
申请日:
2013.01.25
申请国别(地区):
US
年份:
2013
代理人:
摘要:
Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.